Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

References for PMC Articles for PubMed (Select 23391723)


TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer.

Bruna A, Greenwood W, Le Quesne J, Teschendorff A, Miranda-Saavedra D, Rueda OM, Sandoval JL, Vidakovic AT, Saadi A, Pharoah P, Stingl J, Caldas C.

Nat Commun. 2012;3:1055. doi: 10.1038/ncomms2039.


PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population.

Yoon CH, Kim MJ, Lee H, Kim RK, Lim EJ, Yoo KC, Lee GH, Cui YH, Oh YS, Gye MC, Lee YY, Park IC, An S, Hwang SG, Park MJ, Suh Y, Lee SJ.

J Biol Chem. 2012 Jun 1;287(23):19516-27. doi: 10.1074/jbc.M111.337428. Epub 2012 Apr 16.


Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.

Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L.

Clin Cancer Res. 2012 Feb 15;18(4):1109-19. doi: 10.1158/1078-0432.CCR-11-2762. Epub 2012 Jan 10.


A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.


Exploring anti-TGF-β therapies in cancer and fibrosis.

Hawinkels LJ, Ten Dijke P.

Growth Factors. 2011 Aug;29(4):140-52. doi: 10.3109/08977194.2011.595411. Epub 2011 Jun 30. Review.


Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM.

Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK, Wang SE.

Oncogene. 2011 Mar 24;30(12):1470-80. doi: 10.1038/onc.2010.531. Epub 2010 Nov 22.


Targeting breast cancer stem cells.

McDermott SP, Wicha MS.

Mol Oncol. 2010 Oct;4(5):404-19. doi: 10.1016/j.molonc.2010.06.005. Epub 2010 Jun 17. Review.


RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA.

Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24.


Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M.

Mol Cancer. 2010 May 26;9:122. doi: 10.1186/1476-4598-9-122.


Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.

Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.

Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9.


CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS.

J Clin Invest. 2010 Feb;120(2):485-97. doi: 10.1172/JCI39397. Epub 2010 Jan 4.


Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers.

Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ, Lee WH.

PLoS One. 2009 Dec 21;4(12):e8377. doi: 10.1371/journal.pone.0008377.


Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.


ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.

Hu Y, Smyth GK.

J Immunol Methods. 2009 Aug 15;347(1-2):70-8. doi: 10.1016/j.jim.2009.06.008. Epub 2009 Jun 28.


Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS.

Cancer Res. 2009 Feb 15;69(4):1302-13. doi: 10.1158/0008-5472.CAN-08-2741. Epub 2009 Feb 3.


Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Visvader JE, Lindeman GJ.

Nat Rev Cancer. 2008 Oct;8(10):755-68. doi: 10.1038/nrc2499. Epub 2008 Sep 11. Review.


NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs.

Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S, Stewart R, Thomson JA.

Cell Stem Cell. 2008 Aug 7;3(2):196-206. doi: 10.1016/j.stem.2008.07.001.


The epithelial-mesenchymal transition generates cells with properties of stem cells.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA.

Cell. 2008 May 16;133(4):704-15. doi: 10.1016/j.cell.2008.03.027.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk